Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 44 of 44 entries
View as:

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05990452 Org: User:
Start: 08/28/23 End: 12/30/26 Due: 12/30/27

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Phase: N/A Priority: Normal
NCT ID: NCT04554056 Org: User:
Start: 09/21/20 End: 11/05/22 Due: 11/05/23

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05773937 Org: User:
Start: 06/21/22 End: 12/31/24 Due: 12/31/25

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05911984 Org: User:
Start: 06/30/23 End: 03/31/24 Due: 03/31/25

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05740475 Org: User:
Start: 03/20/23 End: 09/30/23 Due: 09/30/24

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06592326 Org: User:
Start: 08/22/24 End: 12/31/28 Due: 12/31/29

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06079112 Org: User:
Start: 09/27/23 End: 12/31/27 Due: 12/31/28

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05416749 Org: User:
Start: 08/05/22 End: 03/31/26 Due: 03/31/27

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04798326 Org: User:
Start: 06/25/19 End: 02/26/20 Due: 02/26/21

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06947226 Org: User:
Start: 04/30/25 End: 04/30/27 Due: 04/30/28

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06492005 Org: User:
Start: 07/26/24 End: 07/31/27 Due: 07/31/28

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Phase: N/A Priority: Normal
NCT ID: NCT05339802 Org: User:
Start: 02/16/22 End: 12/31/23 Due: 12/31/24

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT05324592 Org: User:
Start: 02/26/21 End: 01/25/22 Due: 01/25/23

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Phase: N/A Priority: Normal
NCT ID: NCT06389942 Org: User:
Start: 03/10/23 End: 05/31/24 Due: 05/31/25

A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04627584 Org: User:
Start: 12/29/20 End: 09/30/21 Due: 09/30/22

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06692166 Org: User:
Start: 09/10/24 End: 12/31/29 Due: 12/31/30

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04478461 Org: User:
Start: 09/03/20 End: 02/02/23 Due: 02/02/24

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06926998 Org: User:
Start: 04/15/25 End: 05/01/27 Due: 05/01/28

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05446688 Org: User:
Start: 09/01/22 End: 09/01/24 Due: 09/01/25